Synlogic (SYBX) Q3 2024 earnings summary

Executive summary

• Discontinued lead Phase 3 trial (Synpheny-3) for PKU after internal review indicated unlikely success; no safety concerns cited.

• Undertook major corporate restructuring, reducing workforce by over 90% and shifting focus to strategic alternatives, including a potential merger or sale.

• Exploring strategic alternatives, including potential acquisition, merger, or business combination, with Lucid Capital Markets as advisor.

• No decisions or timetable set for the strategic review process.

• Pipeline deprioritized; current activities limited to strategic review and value enhancement for shareholders.

Financial highlights

• Net loss of $0.1 million for Q3 2024, down from $12.1 million in Q3 2023; net loss of $22.6 million for the nine months ended September 30, 2024, down from $42.7 million year-over-year.

• Revenue was $0 for Q3 2024 (vs. $0.4 million prior year), and $0.01 million for the nine months (vs. $0.6 million prior year), reflecting the end of the Roche collaboration.

• Research and development expenses decreased to a gain of $0.7 million in Q3 2024 (from $9.6 million), and to $9.2 million for the nine months (from $33.8 million), driven by trial discontinuation, workforce reduction, and clinical trial closeout refunds.

• General and administrative expenses were $1.2 million, down from $3.4 million year-over-year.

• Cash and cash equivalents at September 30, 2024 were $19.4 million, down from $75.6 million at year-end 2023.

Outlook and guidance

• Current cash and cash equivalents expected to fund operations at current levels for at least 12 months from filing date.

• Expenses projected to decrease further due to halted clinical activities and reduced headcount.

• Strategic review ongoing; no assurance of successful transaction or value enhancement.

• Forward-looking statements highlight substantial risks and uncertainties, including the outcome of the strategic review and availability of suitable transaction partners.